<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytotoxic chemotherapy remains the mainstay of the medical -management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and has contributed to the rational development of <z:chebi fb="0" ids="35610">antineoplastics</z:chebi> that target these mechanisms </plain></SENT>
<SENT sid="2" pm="."><plain>During <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, genetic changes often occur in molecules that play key functional roles in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> such as cell proliferation, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, cell <z:hpo ids='HP_0011420'>death</z:hpo> and immune-mediated destruction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we review novel <z:chebi fb="0" ids="35610">antineoplastics</z:chebi> that are approved or in development for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> that target molecules associated with genetic aberrations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Some of these targeted <z:chebi fb="0" ids="35610">antineoplastics</z:chebi> have proven effective against other <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and hold promise in treating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> whereas others are now routinely used in combination with cytotoxic agents </plain></SENT>
<SENT sid="5" pm="."><plain>This article reviews <z:chebi fb="0" ids="35610">antineoplastics</z:chebi> that target genetic changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, their antitumor mechanisms, and their stage of development </plain></SENT>
</text></document>